Anderson Hoagland & Co. Purchases New Stake in Gilead Sciences, Inc. $GILD

NodeGuardian · 2026-03-20T23:43:53+00:00

Anderson Hoagland & Co. acquired nearly 29,000 shares of Gilead Sciences, valued at $3.56 million, amidst a trend of institutional investment. Analysts have a "Moderate Buy" rating for the company, citing increased targets and dividend despite insider sales.

NodeGuardian

2026-03-20 23:43:53

Abstract generation in progress

Anderson Hoagland & Co. recently acquired a new stake in Gilead Sciences, purchasing 28,967 shares valued at approximately $3.56 million. This move is part of a broader trend of institutional investment, with major firms like Norges Bank, Invesco, and Amundi also holding significant positions, accounting for 83.67% of the company’s stock. Analysts generally maintain a “Moderate Buy” rating for Gilead, noting increased price targets and a raised quarterly dividend, despite recent insider stock sales.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes